Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026)
Stoke Therapeutics (STOK) posted quarterly Other Non Operating Income of $18000.0 for Q1 2026, down 35.71% year-over-year from $28000.0 in Q1 2025, and up 116.36% quarter-over-quarter from -$110000.0 in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non Operating Income history runs 8 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 35.71% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at -$61000.0 (down 129.19% YoY), while the FY2025 annual figure was -$51000.0, up 79.35% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $18000.0, up from -$110000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $201000.0 in Q4 2024, with the low at -$428000.0 in Q1 2024.
- The 5-year median for Other Non Operating Income is $41000.0 (2023), against an average of $3117.6.
- Peak annual rise in Other Non Operating Income reached 390.24% in 2024, while the deepest fall reached 1119.05% in 2024.
- Stoke Therapeutics' Other Non Operating Income stood at $42000.0 in 2022, then declined by 2.38% to $41000.0 in 2023, then soared by 390.24% to $201000.0 in 2024, then sank by 154.73% to -$110000.0 in 2025, then jumped by 116.36% to $18000.0 in 2026.
- Business Quant data shows STOK's Other Non Operating Income at $18000.0 in Q1 2026, -$110000.0 in Q4 2025, and $3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 308,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | -428,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 42,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 42,000.00 |